Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder
Data Demonstrate Safety and Efficacy of Brexpiprazole in Patients with Schizophrenia Experiencing Severe Psychotic Symptoms
Otsuka and Patrick J. Kennedy Lead Policy Forum Celebrating 10th Anniversary of Mental Health Parity and Addiction Equity Act
Otsuka Pharmaceutical Development & Commercialization, Inc. Hosts Roundtable on Healthcare and Technology with U.S. Representative Bonnie Watson Coleman
Otsuka Announces First Collaboration Agreement to Bring the ABILIFY MYCITE® System to the US Market
Otsuka Pharmaceutical to Acquire Visterra
Otsuka and Lundbeck's Rxulti® (brexpiprazole) approved by the European Commission.
Rxulti® (brexpiprazole) has been approved for the treatment of schizophrenia in adults.
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
Otsuka’s JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Otsuka Encourages Start-Ups to Spark the Next Generation of Innovation and Collaboration in Mental Health Care